Biodiversity Exploitation Fuels Pharma Profits: How Colonial Extraction & Market Failures Threaten Both Nature and Medicine
Original framing: “Biodiversity Is Pharma’s Largest, Oldest And Most Under-Priced Supplier” — bing news
The **trickster Coyote** might laugh at pharma’s 'supply chain risk' framing, exposing it as a **smokescreen for continued theft**—just as Hermes (Greek trickster) stole Apollo’s cattle, pharma 'discovers' Indigenous medicines while hiding behind patents. **Erasmus’s *Praise of Folly*** would mock the solemnity of 'nature restoration' as a **neoliberal greenwash**, while **Anansi’s spider tales** reveal how the 'web of life' is being unraveled by corporate greed. The absurdity lies in calling this a 'market failure' when it’s a **structural success**—one that externalizes costs onto the Global South and future generations.
The crisis of biodiversity exploitation in pharma is not a 'supply chain risk' but a **colonial continuity**, where **extractive capitalism** and **intellectual property regimes** (e.g.
, TRIPS, UPOV) have turned Indigenous knowledge into a **genetic commons to be plundered**. Historical patterns—from **cinchona bark monopolies** to **quinine extraction**—reveal how **racial capitalism** has always treated the Global South as a **pharmaceutical laboratory**, with today’s 'innovation' built on stolen knowledge. Cross-cultural comparisons show that **Indigenous stewardship models** (e.g., *sacred seed banks*, *relational sovereignty*) offer viable alternatives, yet they are excluded from mainstream 'solutions' that prioritize **corporate profit over justice**. The trickster perspective exposes the absurdity of framing this as a 'market failure' when it’s a **structural success**—one that externalizes costs onto marginalized communities and future generations. **Solution pathways** must center **Indigenous self-determination**, **debt reparations**, and **open-source commons** to break the cycle, as historical precedents (e.g., **Andean *Ley de Biodiversidad*, Maori *Te Urewera*) demonstrate. The choice is between **continued exploitation** or a **regenerative paradigm** where biodiversity is valued as **kin, not commodity**.